TY  - JOUR
AU  - Pulido, Federico
AU  - Ribera, Esteban
AU  - Lagarde, Maria
AU  - Perez-Valero, Ignacio
AU  - Palacios, Rosario
AU  - Iribarren, Jose A.
AU  - Payeras, Antoni
AU  - Domingo, Pere
AU  - Sanz, Jose
AU  - Cervero, Miguel
AU  - Curran, Adrian
AU  - Rodriguez-Gomez, Francisco J.
AU  - Tellez, Maria J.
AU  - Ryan, Pablo
AU  - Barrufet, Pilar
AU  - Knobel, Hernando
AU  - Rivero, Antonio
AU  - Alejos, Belen
AU  - Yllescas, Maria
AU  - Arribas, Jose R.
PY  - 2017
DO  - 10.1093/cid/cix734
SN  - 1058-4838
UR  - http://hdl.handle.net/10668/18942
T2  - Clinical infectious diseases
AB  - Background. Our objective was to assess the therapeutic noninferiority of dual therapy with darunavir/ritonavir and lamivudine compared to triple therapy with darunavir/ritonavir plus 2 nucleos(t)ides for maintenance of human immunodeficiency virus...
LA  - en
PB  - Oxford University Press
KW  - Darunavir/ritonavir
KW  - Lamivudine
KW  - Switch
KW  - Dual therapy
KW  - Adult
KW  - Adult
KW  - Anti-HIV Agents
KW  - CD4 Lymphocyte Count
KW  - Darunavir
KW  - Dideoxynucleosides
KW  - Emtricitabine
KW  - Female
KW  - HIV Infections
KW  - HIV Protease Inhibitors
KW  - HIV-1
KW  - Humans
KW  - Lamivudine
KW  - Male
KW  - Medication Therapy Management
KW  - Middle Aged
KW  - RNA, Viral
KW  - Ritonavir
KW  - Tenofovir
KW  - Viral Load
TI  - Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial
TY  - research article
VL  - 65
ER  -